Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
about
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalCell adhesion and urothelial bladder cancer: the role of cadherin switching and related phenomenaMetastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.Differentiation therapy: sesamin as an effective agent in targeting cancer stem-like side population cells of human gallbladder carcinomaEphrin type‑A receptor 2 regulates sensitivity to paclitaxel in nasopharyngeal carcinoma via the phosphoinositide 3‑kinase/Akt signalling pathwayPIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3β/CTNNB1 signaling pathway.Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.Can we safely target the WNT pathway?Polyphenols from marine brown algae target radiotherapy-coordinated EMT and stemness-maintenance in residual pancreatic cancerThe evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapiesmiR-150 Suppresses the Proliferation and Tumorigenicity of Leukemia Stem Cells by Targeting the Nanog Signaling Pathway.The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.Safely targeting cancer stem cells via selective catenin coactivator antagonism.Signaling pathways in HPV-associated cancers and therapeutic implications.Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'.Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms.CD38 is a putative functional marker for side population cells in human nasopharyngeal carcinoma cell lines.BASI, a potent small molecular inhibitor, inhibits glioblastoma progression by targeting microRNA-mediated β-catenin signaling.Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.Cancer stem cells as key drivers of tumour progression.
P2860
Q26744536-43F680B5-6D3C-4434-856F-831236EBE304Q26860953-06EEFCFA-4215-4918-822D-A70D15D6C898Q30639268-6C4A1700-F605-45B0-8DE1-354B07A71E4EQ33926141-BC360923-9938-4526-806F-D3BA8F3C827DQ34028959-F3961C72-E5BC-4326-8EBF-3461927C82B3Q34467897-1D495F91-E09C-412A-B6AE-36515D11B858Q34673530-EE4F536D-31BE-4D41-963B-B7D5BFA0D8CAQ35165755-DB2E6EF1-22C3-40A8-873C-4077981307F7Q35505126-0661A1FB-92BD-4C0D-A69E-CC65877899A3Q35591995-E16A9A9A-AABB-4945-A2CD-DD1AF0861FF4Q36082969-99071E79-B7DE-4A8A-880B-161024BA2D4BQ36515479-71FD6D41-C93F-4E55-831B-7A8627C864D1Q37421084-6E7EAEC3-E636-4578-B8C0-5FF0B650387AQ38175044-9207D0AB-B745-4B77-875A-937222265815Q38224211-646575BF-BAD6-4024-9BAD-495A4E7644F6Q38370778-FC67C68C-8351-4C73-BB4A-7C34A34BD5F4Q38474990-44025446-C679-48A1-A9BD-3E9CF8FBA27BQ38569786-7909F56A-4FF8-4F94-AF76-5889EAD15899Q38915605-D09AEC4B-2F08-4EEC-8459-AEEBEC244A4AQ38997147-10366ACD-50AA-467D-8859-6223A5695D30Q39095223-E74FBAE4-9986-4291-9E1E-0D51F6560C06Q41083994-1603502B-4DD5-4DC6-AAE6-80C8A0E2C16DQ43869209-6B1EE738-9B19-4483-A2FC-4D0732640084Q55122201-76A09181-1AB3-4212-8B49-47F0BC915EEA
P2860
Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@ast
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@en
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@nl
type
label
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@ast
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@en
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@nl
prefLabel
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@ast
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@en
Cancer cells acquire a drug re ...... I3K/Akt/β-catenin/CBP pathway.
@nl
P2093
P2860
P356
P1476
Cancer cells acquire a drug re ...... PI3K/Akt/β-catenin/CBP pathway
@en
P2093
Alexander Ring
Amir Goldkorn
Michael Kahn
Yucheng Xu
P2860
P356
10.1002/IJC.28341
P50
P577
2013-08-05T00:00:00Z